Antibiotiki v dermatovenerologicheskoy praktike


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article discusses in detail the principles of rational choice of antimicrobials in dermatovenerology, its objectives and risk factors. The data on the effectiveness of macrolides are presented. Particular attention is paid to roxithromycin (Esparoxy), which combines a wide spectrum of antimicrobial activity, good pharmacokinetic properties, favorable tolerability profile and usability. The results of clinical trials indicating high efficacy and safety of drug in bacterial infections of various localization, including urogenital tract and skin, are presented. The article considers data on health-care action of Balzamed preparations, actively restoring the barrier function of the skin and preventing the development of infectious complications.

全文:

受限制的访问

参考

  1. Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Практическое руководство по антиинфекционной химиотерапии. Смоленск, 2007. C. 32-46.
  2. Verspotten A., Bolokhovets G., Ghazaryan L., Abilova V., Pyshnik G., Spasojevic T., Korinteli I., Raka L., Kambaralieva B., Cizmovic L., Carp A., Radonjic V., Maqsudova N., Celik H.D., Payerl-Pal M., Pedersen H.B., Sautenkova N., Goossens H.; WHO/Europe-ESAC Project Group. Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe. Lancet Infect. Dis. 2014; 14: 381-87.
  3. VanBoeckel T.P., Gandra S., Ashok A., Caudron Q., Grenfell B.T., Levin S.A., Laxminarayan R. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect. Dis. 2014;14: 742-50.
  4. Den Heijer C.D., van Bijnen M.E., Paget W.J., Pringle M., Goossens H., Bruggeman C.A., Schellevis F.G., Stobberingh E.E.; APRES Study Team. Prevalence and resistance of commensal Staphylococcus aureus, including methicillin-resistant S aureus, in nine European countries: a cross-sectional study. Lancet Infect. Dis. 2013; 13: 409-15.
  5. Халдин А.А. Рациональная антибактериальная терапия в практике дерматовенеролога. РМЖ, 2005; 13(5): 273-77.
  6. Гучев И.А., Сидоренко С.В., Французов В.Н. Рациональная антимикробная химиотерапия инфекций кожи и мягких тканей. Антибиотики и химиотерапия. 2003; 48(10): 25-31.
  7. Яковлев С.В., Ухтин С.А. Азитромицин: основные свойства, оптимизация режимов применения на основе фармакокинетических и фармакодинамических параметров. Антибиотики и химиотерапия. 2003; 48(2): 22-7.
  8. Белоусова Т.А. Каюмова Л.Н., Горячки на М.В. Системные антибиотики в терапии бактериальных инфекций кожи и мягких тканей: фокус на макролиды. РМЖ. 2011; 5: 1317-23.
  9. Ушкалова Е.А. Рокситромицин -перспективный антибиотик из класса макролидов. Фарматека. 2005; 4-5.
  10. http://www.esparma-gmbh.ru/drugs/esparoksi/
  11. Zara G., Qin X.Y., Pilot M.A., et al. Response of the human gastrointestinal tract to erythromycin. J. Gastrointest. Motil. 1991; 3: 26-31.
  12. Бакумова О.Р., Шахова Е.Г. Роль макролидов в патологии ЛОР-органов. Фарматека. 2014; 10: 91-4.
  13. Craig W.A., Gudmundson S. Postantibiotic effect. In: Antibiotics in Laboratory Medicine. V. Lorian (Ed.). Baltimore etc., 1996. С. 403-31.
  14. Bergogne-Berezin E. Clinical significance of studies on antibiotic concentrations in the lower respiratory tract. In: Predicting Antibiotic Response in Respiratory Tract Infections. Highlights from the 7th International Congress for Infectious Diseases. Hong Kong. 1996. 7-8.
  15. Yamada T., Fujieda S., Mori S., Yamamoto H., Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am. J. Rhinol. 2000; 14(3): 143-48.
  16. Snyman J.R., Schoeman H.S., Grobusch M.P., Henning M., Rabie W., Hira M., Parshotam K., Mithal Y., Singh S., Ramdas Z.Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study. Clin. Drug. Invest. 2009; 29: 265-74.
  17. Kanoh S., Rubin B.K. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 2010; 23(3): 590-615.
  18. Zhang M., Li Y., Wang Z., Li P., Zhang G., Zhang Q. Effect of clarithromycin on the expressions of cyclooxygenase-2 and nuclear factor-kappa В in nasal polyps in vitro. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009; 23(17): 769-72.
  19. Егорова О.А. Применение препарата Эспарокси в лечение инфекций ЛОР-органов. Фарматека. 2014; 15: 69-74.
  20. Гаращенко Т.И. Макролиды в терапии острого тонзиллита и его осложнений у детей. РМЖ. 2001; 9: 19-23.
  21. Макеева И.М., Ерохин А.И., Гостев М.С. Клинический опыт использования препарата Эспарокси в комплексном лечении одонтогенного синусита. Фарматека. 2013; 13: 17-9.
  22. Lassus A., Seppala A. Roxithromycin in nongonococcal urethritis. J. Antimicrob. Chemother. 1987; 20(Suppl. B): 157-65.
  23. van Schouwenburg J., de Bruyn O., Fourie E., et al. A randomized, comparative study of the efficacy and tolerance of roxithromycin and doxycycline in the treatment of women with positive endocervical cultures for Chlamydia trachomatis and Mycoplasma spp. in an in vitro fertilization program. Diagn. Microbiol. Infect. Dis. 1992; 15(Suppl. 4): 129-31.
  24. Radowicki S., Tyc M., Kulesza E., Dowgiallo-Smolarczyk J. Roxithromycin (Rulid) in treatment of Chlamydia trachomatis genital infections in women. Ginekol. Pol. 1995; 66: 354-56.
  25. Agache P., Amblard P., Moulin G., Barriere H., Texier L., Beylot C., Bergoend H. Roxithromycin in skin and soft tissue infections. J. Antimicrob. Chemother. 1987; 20(Suppl. B): 153-56.
  26. Pechere J.C. Clinical evaluation of roxithromycin 300 mg once daily as an alternative to 150 mg twice daily. Diagn. Microbiol. Infect. Dis. 1992; 15(Suppl. 4): 111-17.
  27. Yamasaki O., Akiyama H., Toi Y., Arata J. A combination of roxithromycin and imipenem as an antimicrobial strategy against biofilms formed by Staphylococcus aureus. J. Antimicrob. Chemother. 2001; 48: 573-77.
  28. Bernard P., Plantin P., Roger H., Sassolas B., Villaret E., Legrain V., Roujeau J.C., Rezvani Y., Scheimberg A. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br. J. Dermatol. 1992; 127: 155-95.
  29. Ferahbas A., Utas S., Aykol D., Borlu M., Uksal U. Clinical evaluation of roxithromycin: a doubleblind, placebo-controlled and crossover trial in patients with acne vulgaris. J. Dermatol. 2004; 31: 6-9.
  30. Hayashi N., Kawashima M. Efficacy of oral antibiotics on acne vulgaris and their effects on quality of life: a multicenter randomized controlled trial using minocycline, roxithromycin and faropenem. J. Dermatol. 2011; 38(2): 111-19.
  31. Круглова Л.С., Жукова О.В, Стенько А.Г Предикторы и коррекция ксероза при локализации процесса на стопах. Фарматека. 2014; 6: 13-7.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2015
##common.cookie##